Literature DB >> 19930399

Magnetic resonance spectroscopy of regional brain metabolite markers in FALS mice and the effects of dietary creatine supplementation.

Ji-Kyung Choi1, Ekkehard Küstermann, Alpaslan Dedeoglu, Bruce G Jenkins.   

Abstract

We investigated the effects of disease progression on brain regional neurochemistry in a mutant mouse model of familial amyotrophic lateral sclerosis (FALS; the G93A model) using in vivo and in vitro magnetic resonance spectroscopy (MRS). There were numerous changes in the brain spectra that were brain region dependent. At early time points starting around 80 days of age there were increases in brain glutamate. At later time points there were more extensive changes including decreased N-acetyl aspartate and glutamate and increased glutamine, taurine and myo-inositol. The effects of the disease were most severe in spinal cord followed by medulla and then sensorimotor cortex. There were no changes noted in cerebellum as a control region. The effects of creatine supplementation in the diet (2%) were measured in wild-type and FALS animals in medulla, cerebellum and cortex. The increase in brain creatine was largest in cerebellum (25%) followed by medulla (11%) and then cortex (4%), reflecting the ordering of creatine kinase activity. There was a protective effect of creatine on N-acetyl aspartate loss in the medulla at late stages. Creatine supplementation had a positive effect on weight retention, leading to a 13% increase in weight between 120 and 130 days. MRS shows promise in monitoring multiple facets of neuroprotective strategies in ALS and ALS models.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19930399      PMCID: PMC2846694          DOI: 10.1111/j.1460-9568.2009.07015.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  36 in total

1.  Effect of creatine supplementation on metabolite levels in ALS motor cortices.

Authors:  S Vielhaber; J Kaufmann; M Kanowski; M Sailer; H Feistner; C Tempelmann; C E Elger; H J Heinze; W S Kunz
Journal:  Exp Neurol       Date:  2001-12       Impact factor: 5.330

2.  Nonlinear decrease over time in N-acetyl aspartate levels in the absence of neuronal loss and increases in glutamine and glucose in transgenic Huntington's disease mice.

Authors:  B G Jenkins; P Klivenyi; E Kustermann; O A Andreassen; R J Ferrante; B R Rosen; M F Beal
Journal:  J Neurochem       Date:  2000-05       Impact factor: 5.372

3.  Metabolic changes in quinolinic acid-lesioned rat striatum detected non-invasively by in vivo (1)H NMR spectroscopy.

Authors:  I Tkác; C D Keene; J Pfeuffer; W C Low; R Gruetter
Journal:  J Neurosci Res       Date:  2001-12-01       Impact factor: 4.164

4.  Increases in cortical glutamate concentrations in transgenic amyotrophic lateral sclerosis mice are attenuated by creatine supplementation.

Authors:  O A Andreassen; B G Jenkins; A Dedeoglu; K L Ferrante; M B Bogdanov; R Kaddurah-Daouk; M F Beal
Journal:  J Neurochem       Date:  2001-04       Impact factor: 5.372

5.  A randomized sequential trial of creatine in amyotrophic lateral sclerosis.

Authors:  G J Groeneveld; Jan H Veldink; Ingeborg van der Tweel; Sandra Kalmijn; Cornelis Beijer; Marianne de Visser; John H J Wokke; Hessel Franssen; Leonard H van den Berg
Journal:  Ann Neurol       Date:  2003-04       Impact factor: 10.422

Review 6.  In vivo NMR studies of neurodegenerative diseases in transgenic and rodent models.

Authors:  In-Young Choi; Sang-Pil Lee; David N Guilfoyle; Joseph A Helpern
Journal:  Neurochem Res       Date:  2003-07       Impact factor: 3.996

7.  Magnetic resonance spectroscopic analysis of Alzheimer's disease mouse brain that express mutant human APP shows altered neurochemical profile.

Authors:  Alpaslan Dedeoglu; Ji-Kyung Choi; Kerry Cormier; Neil W Kowall; Bruce G Jenkins
Journal:  Brain Res       Date:  2004-06-25       Impact factor: 3.252

Review 8.  Disease-modifying therapies for Alzheimer disease: challenges to early intervention.

Authors:  Jeffrey L Cummings; Rachelle Doody; Christopher Clark
Journal:  Neurology       Date:  2007-10-16       Impact factor: 9.910

9.  Creatine supplementation and riluzole treatment provide similar beneficial effects in copper, zinc superoxide dismutase (G93A) transgenic mice.

Authors:  R J Snow; J Turnbull; S da Silva; F Jiang; M A Tarnopolsky
Journal:  Neuroscience       Date:  2003       Impact factor: 3.590

Review 10.  MRI monitoring of MS in clinical trials.

Authors:  David H Miller
Journal:  Clin Neurol Neurosurg       Date:  2002-07       Impact factor: 1.876

View more
  17 in total

1.  Evolution of the neurochemical profiles in the G93A-SOD1 mouse model of amyotrophic lateral sclerosis.

Authors:  Hongxia Lei; Elisabeth Dirren; Carole Poitry-Yamate; Bernard L Schneider; Rolf Gruetter; Patrick Aebischer
Journal:  J Cereb Blood Flow Metab       Date:  2018-02-05       Impact factor: 6.200

Review 2.  Use of biomarkers in ALS drug development and clinical trials.

Authors:  Nadine Bakkar; Ashley Boehringer; Robert Bowser
Journal:  Brain Res       Date:  2014-10-24       Impact factor: 3.252

Review 3.  Preclinical (1)H-MRS neurochemical profiling in neurological and psychiatric disorders.

Authors:  Moonnoh R Lee; Aleksandar Denic; David J Hinton; Prasanna K Mishra; Doo-Sup Choi; Istvan Pirko; Moses Rodriguez; Slobodan I Macura
Journal:  Bioanalysis       Date:  2012-07       Impact factor: 2.681

4.  Proton MR spectroscopy-detectable major neurotransmitters of the brain: biology and possible clinical applications.

Authors:  N Agarwal; P F Renshaw
Journal:  AJNR Am J Neuroradiol       Date:  2011-12-29       Impact factor: 3.825

5.  Omics to Explore Amyotrophic Lateral Sclerosis Evolution: the Central Role of Arginine and Proline Metabolism.

Authors:  Franck Patin; Philippe Corcia; Patrick Vourc'h; Lydie Nadal-Desbarats; Thomas Baranek; Jean-François Goossens; Sylviane Marouillat; Anne-Frédérique Dessein; Amandine Descat; Blandine Madji Hounoum; Clément Bruno; Samuel Leman; Christian R Andres; Hélène Blasco
Journal:  Mol Neurobiol       Date:  2016-09-02       Impact factor: 5.590

Review 6.  Bioavailability, Efficacy, Safety, and Regulatory Status of Creatine and Related Compounds: A Critical Review.

Authors:  Richard B Kreider; Ralf Jäger; Martin Purpura
Journal:  Nutrients       Date:  2022-02-28       Impact factor: 5.717

7.  Enhanced Cortical Metabolic Activity in Females and Males of a Slow Progressing Mouse Model of Amyotrophic Lateral Sclerosis.

Authors:  Dipak Roy; Madhuri Puvvada; Sampath K T Kapanaiah; Anant Bahadur Patel
Journal:  Neurochem Res       Date:  2022-03-26       Impact factor: 3.996

Review 8.  Transcriptomics and Metabolomics in Amyotrophic Lateral Sclerosis.

Authors:  Marios G Krokidis
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

9.  Disruption of TCA Cycle and Glutamate Metabolism Identified by Metabolomics in an In Vitro Model of Amyotrophic Lateral Sclerosis.

Authors:  Charlotte Veyrat-Durebex; Philippe Corcia; Eric Piver; David Devos; Audrey Dangoumau; Flore Gouel; Patrick Vourc'h; Patrick Emond; Frédéric Laumonnier; Lydie Nadal-Desbarats; Paul H Gordon; Christian R Andres; Hélène Blasco
Journal:  Mol Neurobiol       Date:  2015-12-14       Impact factor: 5.590

Review 10.  Roles of vitamin D in amyotrophic lateral sclerosis: possible genetic and cellular signaling mechanisms.

Authors:  Khanh vinh quốc Long; Lan Thi Hoàng Nguyễn
Journal:  Mol Brain       Date:  2013-04-09       Impact factor: 4.041

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.